Who
Marc Duey
Director
Company insider
Files Form 4 as: Director, Aprea Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 3
- Sells
- 1
- Bought
- $157K
- Sold
- $30K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 28 Jul 2022
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 10 Dec 2025filed 11 Dec 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —21,459 | filing |
| 10 Dec 2025filed 11 Dec 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K21,459 at $1.17 | filing |
| 5 Jun 2025filed 9 Jun 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,045 at $0.00 | filing |
| 18 Oct 2024filed 25 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K6,462 at $4.58 | filing |
| 16 Oct 2024filed 17 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $132K30,000 at $4.39 | filing |
| 14 Oct 2024filed 16 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $490190 at $2.58 | filing |
| 20 Jun 2024filed 21 Jun 2024 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,045 at $0.00 | filing |
| 23 Aug 2023filed 24 Aug 2023 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Aug 2023filed 24 Aug 2023 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —500 at $0.00 | filing |
| 23 Aug 2022filed 24 Aug 2023 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —400,969 at $0.00 | filing |
| 23 Aug 2022filed 24 Aug 2023 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,161 at $0.00 | filing |
| 23 Aug 2022filed 24 Aug 2023 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code C | —4,009,690 at $0.00 | filing |
| 23 Aug 2022filed 24 Aug 2023 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code C | —11,610 at $0.00 | filing |
| 28 Jul 2022filed 1 Aug 2022 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,575 at $0.00 | filing |
News
Reviewing Aprea Therapeutics (NASDAQ:APRE) & CRISPR Therapeutics (NASDAQ:CRSP)APRE · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Marc Duey; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.